Candriam S.C.A. lifted its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 19.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 745,057 shares of the company’s stock after buying an additional 119,143 shares during the quarter. Candriam S.C.A.’s holdings in Keros Therapeutics […]
Brokerages Set Keros Therapeutics, Inc (NASDAQ:KROS) Target Price at $94 33 kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics (NASDAQ:KROS) Given Outperform Rating at Wedbush themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) issued its earnings results on Monday. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.34) by $0.07, Briefing.com reports. During the same period in the previous year, the company earned ($1.13) EPS. Keros Therapeutics Stock Down 8.7 % Shares of NASDAQ:KROS opened at […]
Keros Therapeutics (NASDAQ:KROS – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.07, Briefing.com reports. During the same quarter last year, the firm earned ($1.13) earnings per share. Keros Therapeutics Price Performance NASDAQ:KROS traded down […]